MiR-155 deficiency ameliorates autoimmune inflammation of systemic lupus erythematosus by targeting S1pr1 in Faslpr/lpr mice

Journal of Immunology

Volumn 194, Issue 11, 2015, Pages 5437-5445

  Xin, Qian ^a   Li, Jiangxia ^a   Dang, Jie ^a   Bian, Xianli ^a   Shan, Shan ^a   Yuan, Jupeng ^a   Qian, Yanyan ^a   Liu, Zhaojian ^a   Liu, Guangyi ^b   Yuan, Qianqian ^a   Liu, Na ^a   Ma, Xiaochun ^a   Gao, Fei ^a   Gong, Yaoqin ^a   Liu, Qiji ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 4; MICRORNA 155; PROTEIN INHIBITOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG; W 146; AUTOANTIBODY; FAS PROTEIN, MOUSE; IL17A PROTEIN, MOUSE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICRORNA; MIRN155 MICRORNA, MOUSE; S1PR1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 CD8 RATIO; CHINA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN TARGETING; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; TH2 CELL; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CELL LINE; CYTOLOGY; DOWN REGULATION; GENETICS; GLOMERULONEPHRITIS; HEK293 CELL LINE; HELPER CELL; IMMUNOLOGY; INFLAMMATION; KIDNEY; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; PATHOLOGY;

ANIMALS; ANTIGENS, CD95; AUTOANTIBODIES; CD4-CD8 RATIO; CELL LINE; DOWN-REGULATION; GLOMERULONEPHRITIS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-4; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; RECEPTORS, LYSOSPHINGOLIPID; T-LYMPHOCYTES, HELPER-INDUCER; TH17 CELLS; TH2 CELLS;

EID: 84929630429     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1403028     Document Type: Article

References (32)

1. Wakeland, E. K., K. Liu, R. R. Graham, and T. W. Behrens. 2001. Delineating the genetic basis of systemic lupus erythematosus. Immunity 15: 397-408.
2. Sanz, I., and F. E. Lee. 2010. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 6: 326-337.
3. Mohan, C., L. Morel, P. Yang, H. Watanabe, B. Croker, G. Gilkeson, and E. K. Wakeland. 1999. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J. Clin. Invest. 103: 1685-1695.
4. Crispín, J. C., M. Oukka, G. Bayliss, R. A. Cohen, C. A. Van Beek, I. E. Stillman, V. C. Kyttaris, Y. T. Juang, and G. C. Tsokos. 2008. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181: 8761-8766.
5. Wong, C. K., L. C. Lit, L. S. Tam, E. K. Li, P. T. Wong, and C. W. Lam. 2008. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 127: 385-393.
6. Zhang, Z., V. C. Kyttaris, and G. C. Tsokos. 2009. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 183: 3160-3169.
7. Bartel, D. P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
8. Baltimore, D., M. P. Boldin, R. M. O'Connell, D. S. Rao, and K. D. Taganov. 2008. MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 9: 839-845.
9. Murugaiyan, G., V. Beynon, A. Mittal, N. Joller, and H. L. Weiner. 2011. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 187: 2213-2221.
10. Kurowska-Stolarska, M., S. Alivernini, L. E. Ballantine, D. L. Asquith, N. L. Millar, D. S. Gilchrist, J. Reilly, M. Ierna, A. R. Fraser, B. Stolarski, et al. 2011. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc. Natl. Acad. Sci. USA 108: 11193-11198.
11. Blüml, S., M. Bonelli, B. Niederreiter, A. Puchner, G. Mayr, S. Hayer, M. I. Koenders, W. B. van den Berg, J. Smolen, and K. Redlich. 2011. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 63: 1281-1288.
12. Jin, H. M., T. J. Kim, J. H. Choi, M. J. Kim, Y. N. Cho, K. I. Nam, S. J. Kee, J. B. Moon, S. Y. Choi, D. J. Park, et al. 2014. MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis. Arthritis Res. Ther. 16: R88.
13. Dai, R., Y. Zhang, D. Khan, B. Heid, D. Caudell, O. Crasta, and S. A. Ahmed. 2010. Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS ONE 5: e14302. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone. 0014302.
14. Wang, G., L. S. Tam, E. K. Li, B. C. Kwan, K. M. Chow, C. C. Luk, P. K. Li, and C. C. Szeto. 2010. Serum and urinary cell-free miR-146a and miR-155 in patients with systemic lupus erythematosus. J. Rheumatol. 37: 2516-2522.
15. Wang, G., L. S. Tam, B. C. Kwan, E. K. Li, K. M. Chow, C. C. Luk, P. K. Li, and C. C. Szeto. 2012. Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus. Clin. Rheumatol. 31: 435-440.
16. Jonsson, R., C. Svalander, and G. Nyberg. 1986. Immune deposits in oral mucosa, skin and kidney in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 4: 231-236.
17. Andrews, B. S., R. A. Eisenberg, A. N. Theofilopoulos, S. Izui, C. B. Wilson, P. J. McConahey, E. D. Murphy, J. B. Roths, and F. J. Dixon. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148: 1198-1215.
18. Perkins, D. L., R. M. Glaser, C. A. Mahon, J. Michaelson, and A. Marshak-Rothstein. 1990. Evidence for an intrinsic B cell defect in lpr/lpr mice apparent in neonatal chimeras. J. Immunol. 145: 549-555.
19. Dudda, J. C., B. Salaun, Y. Ji, D. C. Palmer, G. C. Monnot, E. Merck, C. Boudousquie, D. T. Utzschneider, T. M. Escobar, R. Perret, et al. 2013. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 38: 742-753.
20. Kong, W., L. He, E. J. Richards, S. Challa, C. X. Xu, J. Permuth-Wey, J. M. Lancaster, D. Coppola, T. A. Sellers, J. Y. Djeu, and J. Q. Cheng. 2014. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33: 679-689.
21. O'Connell, R. M., D. Kahn, W. S. Gibson, J. L. Round, R. L. Scholz, A. A. Chaudhuri, M. E. Kahn, D. S. Rao, and D. Baltimore. 2010. MicroRNA- 155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33: 607-619.
22. Kohlhaas, S., O. A. Garden, C. Scudamore, M. Turner, K. Okkenhaug, and E. Vigorito. 2009. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J. Immunol. 182: 2578-2582.
23. Vigorito, E., K. L. Perks, C. Abreu-Goodger, S. Bunting, Z. Xiang, S. Kohlhaas, P. P. Das, E. A. Miska, A. Rodriguez, A. Bradley, et al. 2007. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 27: 847-859.
24. Thai, T. H., H. C. Patterson, D. H. Pham, K. Kis-Toth, D. A. Kaminski, and G. C. Tsokos. 2013. Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Faslpr mouse. Proc. Natl. Acad. Sci. USA 110: 20194-20199.
25. Lu, L. F., T. H. Thai, D. P. Calado, A. Chaudhry, M. Kubo, K. Tanaka, G. B. Loeb, H. Lee, A. Yoshimura, K. Rajewsky, and A. Y. Rudensky. 2009. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30: 80-91.
26. O'Connell, R. M., A. A. Chaudhuri, D. S. Rao, and D. Baltimore. 2009. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. USA 106: 7113-7118.
27. Ceppi, M., P. M. Pereira, I. Dunand-Sauthier, E. Barras, W. Reith, M. A. Santos, and P. Pierre. 2009. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc. Natl. Acad. Sci. USA 106: 2735-2740.
28. Galicia-Rosas, G., N. Pikor, J. A. Schwartz, O. Rojas, A. Jian, L. Summers-Deluca, M. Ostrowski, B. Nuesslein-Hildesheim, and J. L. Gommerman. 2012. A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner. J. Immunol. 189: 3700-3706.
29. Zhao, C., M. J. Fernandes, M. Turgeon, S. Tancrède, J. Di Battista, P. E. Poubelle, and S. G. Bourgoin. 2008. Specific and overlapping sphingosine- 1-phosphate receptor functions in human synoviocytes: impact of TNF-a. J. Lipid Res. 49: 2323-2337.
30. Pan, H. F., R. X. Leng, C. C. Feng, X. P. Li, G. M. Chen, B. Z. Li, W. D. Xu, S. G. Zheng, and D. Q. Ye. 2013. Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus. Mol. Biol. Rep. 40: 391-399.
31. Brinkmann, V., A. Billich, T. Baumruker, P. Heining, R. Schmouder, G. Francis, S. Aradhye, and P. Burtin. 2010. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9: 883-897.
32. Spiegel, S., and S. Milstien. 2011. The outs and the ins of sphingosine-1- phosphate in immunity. Nat. Rev. Immunol. 11: 403-415.